Directors & Officers
| Name | Title | Year Born |
|---|---|---|
| Mr. Junyi Dai | CEO & Chairman | 1987 |
| Mr. Yu Ding | Chief Financial Officer | 1975 |
INDP
Indaptus Therapeutics Inc
CIK
0001857044
Employees
5
Phone
646 427 2727
Fiscal year end
December
IPO
Aug 04, 2015
Address
Three Columbus Circle, New York, NY, United States, 10019
3.34
+0.01 (+0.30%)
USD · NASDAQ
52-week range
0.92
5.96
Trading at 48% of the 52-week range
Market Cap
440.37M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.09
Div. Yield
N/A
% Institutions
0.264%
% Insiders
70.65%
1 Year
+0.0%3 Year
-94.7%10 Year
-100.0%Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Actions
Add an action for INDP.US, or sign in to see your action list.
People
Shareholders
Financial Highlights
Market Cap:
$440.37M
EBITDA:
$-19.83M
Book Value:
$0.09
Earnings/Share:
$-6.15
Profit Margin:
0.00%
Operating Margin:
0.00%
ROA (TTM):
-98.08%
ROE (TTM):
-318.04%
Revenue (TTM):
$0.00
Revenue/Share (TTM):
$0.00
Earnings Growth (YOY):
0.00%
Revenue Growth (YOY):
0.00%
Valuation Metrics
Enterprise Value:
$439.21M
Trailing P/E:
0.00
Forward P/E:
0.00
Shares Statistics
Shares Outstanding:
133.24M
Shares Float:
39.33M
% Insiders:
70.65%
% Institutions:
0.264%
Short % Float:
2.08%
Stock Price History
1 Year Price History
3 Years Price History
10 Years Price History
Max Price History
Financial Charts
Revenue, Net Income & Operating Cash Flow (Yearly)
Change % vs Prior Year
Revenue, Net Income & Operating Cash Flow (Quarterly)
Change % vs Prior Quarter
Operating Expenses (Yearly)
Operating Expenses (Quarterly)
Balance Sheet (Yearly)
Balance Sheet (Quarterly)
Assets Breakdown (Yearly)
Assets Breakdown (Quarterly)
Liabilities Breakdown (Yearly)
Liabilities Breakdown (Quarterly)
Income Statement Waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-10.49M
R&D
adjust
$-9.34M
Operating Income
subtotal
$-19.83M
Other / Non-Operating Items
adjust
$-1.02M
Net Income
subtotal
$-20.85M
Earnings Per Share (EPS) History
Financial Ratios
📦 Raw API Data (JSON Explorer)
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.